期刊文献+

仝小林教授态靶结合辨治1型糖尿病经验 被引量:9

Prof. Tong Xiaolin's Experience in the Treatment of Diabetes Type 1 with “Status-Target” Differentiation
下载PDF
导出
摘要 1型糖尿病是因胰岛功能受损导致胰岛素分泌减少的代谢性疾病,目前注射胰岛素仍然是1型糖尿病的主要治疗手段。仝小林教授认为在胰岛素治疗的同时,配合中医辨治不但可以增加治疗效果,还可以有效的预防和治疗并发症。"态靶因果"的中医辨治方略,不仅能有效地提高临床思维水平,也推动了中西医的互补和结合。对1型糖尿病辨证分型,还可以从患者个体出发,根据血糖、血脂、血压、自身抗体、并发症的不同使用不同的靶药,使得中西医结合达到疗效最大化。 Diabetes Type 1 is a metabolic disease due to decreased insulin secretion resulting from insulin damage. At present,insulin injection is still the main approach to the treatment. Prof. Tong Xiaolin thinks the combination of TCM differentiation with insulin treatment not only increases the therapeutic effects,but also effectively prevents from and treats its complications. The"status-target-cause-result"in TCM differentiation effectively promotes the clinical analytic level and the complementation and combination of TCM and western medicine. Regarding the pattern/syndrome differentiation of diabetes type 1,on the basis of individual situation,the target medication is applied according to blood glucose,blood lipid,blood pressure,self-antibody and complications. The integration of Chinese and western medicine optimizes the therapeutic effects.
作者 顾成娟 王涵 仝小林 GU Cheng-juan WANG Han TONG Xiao-lin(Guanganmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100091)
出处 《世界中西医结合杂志》 2017年第2期178-179,244,共3页 World Journal of Integrated Traditional and Western Medicine
基金 国家自然科学基金资助项目(81430097)
关键词 1型糖尿病 态靶结合 仝小林 Diabetes Type 1 Status-Target Combination Tong Xiaolin
  • 相关文献

参考文献4

二级参考文献27

  • 1王翠娣,郭玉璞.雷公藤的有效成分、药理作用及临床应用[J].中国中西医结合杂志,1993,13(8):507-509. 被引量:34
  • 2苏励,茅建春,顾军花.环磷酰胺联合大剂量黄芪注射液静脉滴注治疗狼疮性肾炎[J].中西医结合学报,2007,5(3):272-275. 被引量:17
  • 3The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report on the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care, 2002,25 ( Suppl 1 ) :S5 -S20.
  • 4Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications (Part 1 ). Diabet Med, 1998,15:539-553.
  • 5Seissler J, de Sonnaville JJ, Morgenthaler NG, et al. Immunological heterogeneity in type 1 diabetes: presence of distinct autoantibody patterns in patients with acute onset and slowly progressive disease.Diabetologia, 1998,41:891-897.
  • 6Greenbaum CJ, Harrison LC. Guidelines for intervention trials in subjects with newly diagnosed type 1 diabetes. Diabetes, 2003,52 :1059-1065.
  • 7Borg H, Gottsllter A, Fernlund P, et al. A 12-year prospective study of the relationship between islet antibodies and β-cell function at and after the diagnosis in patients with adult-onset diabetes. Diabetes, 2002,51 :1754-1762.
  • 8Gor DO, Rose NR, Greenspan NS. TH1-TH2.. a procrustean paradigm. Nat Immunol. 2003, 4(6):503-505.
  • 9Roep BO. The role of T-cells in the pathogenesis of type 1 diabetes: from cause to cure. Diabetologia. 2003; 46 (3) : 305-321.
  • 10Silveira PA, Grey ST. B cells in the spotlight: innocent bystanders or major players in the pathogenesis of type 1 diabetes. Trends Endocrinol Metab. 2006; 17(4): 128- 135.

共引文献214

同被引文献170

引证文献9

二级引证文献42

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部